Transplant atherosclerosis: Role of phenotypic modulation of vascular smooth muscle by nitric oxide

被引:18
作者
Bundy, RE [1 ]
Marczin, N [1 ]
Birks, EF [1 ]
Chester, AH [1 ]
Yacoub, MH [1 ]
机构
[1] Harefield Hosp, Heart Sci Ctr, Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst,Dept Cardiothorac Surg, Harefield UB9 6JH, Middx, England
来源
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM | 2000年 / 34卷 / 02期
关键词
transplantation; coronary artery disease; signal transduction;
D O I
10.1016/S0306-3623(00)00047-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Occlusive accelerated atherosclerosis of coronary grafts is the predominant factor that limits longevity of heart transplant recipients. This form of vascular disease affects both the large epicardial and the smaller intramyocardial vessels, leading to characteristic clinical presentation that necessitates the use of sophisticated techniques for their accurate detection. Accelerated atherosclerosis after transplantation is a multifactorial disease with many events contributing to its progression. The initial vascular injury associated with ischemia-reperfusion appears to aggravate preexisting conditions in the donor vasculature in addition to activation of new immunological and nonimmunological mechanisms. Throughout these events, the endothelium remains a primary target of cell- and humoral-mediated injury. Changes in the vascular intima leads to alterations in vascular smooth muscle cell (VSMC) physiology, resulting in VSMC phenotypic modulation with the orchestration of a broad spectrum of growth and inflammatory reactions, which might be a healing response to vascular injury. Endogenous nitric oxide (NO) pathways regulate a multiplicity of cellular mechanisms that play a major role in determining the structure and function of the vessel wall during normal conditions and during remodeling associated with accelerated atherosclerosis. Recently identified signaling pathways, including mitogen-activated protein kinase, cGMP-dependent protein kinase, phosphatidylinositol 3-kinase. and transcriptional events in which nuclear factor kappa B and activator protein 1 take part, can he associated with NO modulation of cell cycle perturbations and phenotypic alteration of VSMC during accelerated atherosclerosis. This article reviews recent progress covering the aforementioned matters. We start by summarizing the clincal aspects and pathogenesis of accelerated atherosclerosis associated with transplantation, including clinical presentation and detection. This summary is followed by a discussion of the multiple factors of the disease process, including immunological and nonimmunolgical contributions. The next section focuses on cellular responses of the VSMCs relevant to lesion formation, with special emphasis on classical and recent paradigms of phenotypic modulation of these cells. To examine the influence of NO on VSMC phenotypic modulation and consequent lesion development, we briefly overview characteristics of NO production in the normal coronary vascular bed and the changes in endogenous NO release and activity during atherosclerosis, This overview is followed by a section covering molecular mechanisms whereby NO regulates a range of signaling pathways, transcriptional events underlying cell cycle perturbation, and phenotypic alteration of VSMC in accelerated atherosclerosis. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:73 / 84
页数:12
相关论文
共 128 条
[41]   Dual determination of angiotensin-converting enzyme and angiotensin-II type 1 receptor genotypes as predictors of restenosis after coronary angioplasty [J].
Hamon, M ;
Amant, C ;
Bauters, C ;
Richard, F ;
Helbecque, N ;
Passard, F ;
McFadden, EP ;
Lablanche, JM ;
Bertrand, ME ;
Amouyel, P .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (01) :79-+
[42]   REACTION OF NO WITH THE REDUCED R2 PROTEIN OF RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA-COLI [J].
HASKIN, CJ ;
RAVI, N ;
LYNCH, JB ;
MUNCK, E ;
QUE, L .
BIOCHEMISTRY, 1995, 34 (35) :11090-11098
[43]   Differentiated phenotype of smooth muscle cells depends on signaling pathways through insulin-like growth factors and phosphatidylinositol 3-kinase [J].
Hayashi, K ;
Saga, H ;
Chimori, Y ;
Kimura, K ;
Yamanaka, Y ;
Sobue, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (44) :28860-28867
[44]   Changes in the balance of phosphoinositide 3-kinase/protein kinase B (Akt) and the mitogen-activated protein kinases (ERK/p38MAPK) determine a phenotype of visceral and vascular smooth muscle cells [J].
Hayashi, K ;
Takahashi, M ;
Kimura, K ;
Nishida, W ;
Saga, H ;
Sobue, K .
JOURNAL OF CELL BIOLOGY, 1999, 145 (04) :727-740
[45]   Phosphatidylinositol 3-kinase is a target for protein tyrosine nitration [J].
Hellberg, CB ;
Boggs, SE ;
Lapetina, EG .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 252 (02) :313-317
[46]   Diabetes and dyslipidemia - A new model for transplant coronary artery disease [J].
Hoang, K ;
Chen, I ;
Reaven, G ;
Zhang, LN ;
Ross, H ;
Billingham, M ;
Valantine, H .
CIRCULATION, 1998, 97 (21) :2160-2168
[47]  
Hollenberg SM, 1998, J HEART LUNG TRANSPL, V17, P487
[48]  
Hornick P, 1997, CIRCULATION, V96, P148
[49]  
Hosenpud JD, 1995, J HEART LUNG TRANSPL, V14, pS185
[50]   Nitric oxide as a signaling molecule in the vascular system: An overview [J].
Ignarro, LJ ;
Cirino, G ;
Casini, A ;
Napoli, C .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1999, 34 (06) :879-886